

## **Duke File (IDF) Number**

IDF #:T-003968

#### **Meet the Inventors**

Zennadi, Rahima

# **Contact For More Info**

Krishnan, Shweta 919-681-7541 <u>shweta.krishnan@duke.edu</u>

## Department

Department of Medicine (DOM)(Dept. & CRU)

## **Publication(s)**

••

### External Link(s)

• From the lab of Dr. Rahima Zennadi

# G protein-coupled receptor kinase 2 and beta arrestins as therapeutic targets and diagnostic tools for hemoglobinopathies

#### Value Proposition

Sickle cell disease affects millions of people throughout the world. Patients with sickle cell disease often experience episodes of acute pain that are caused by vaso-occlusive crisis. It is the leading cause of a frequent reason for emergency department visits and hospitalization of affected patients. Accordingly, there is an urgent need for innovative therapies to treat and prevent vaso-occlusion in patients with sickle cell disease

#### Technology

Researchers at Duke have conceived a novel therapy for treating or preventing painful vaso-occlusive crises associated with organ damage in patients with sickle cell disease. Beta-arrestins and G protein-coupled receptor kinase 2 are activated in sickle red cells but not in normal red cells. These kinases are involved in adhesion of sickle red blood cells and can promote vasooclusion. Thereby, beta-arrestins and G protein-coupled receptor kinase 2 represent potential therapeutic targets in hemoglobinopathies.